We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+19.33%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$8.08M
Cap. Flow
-$150M
Cap. Flow %
-11.5%
Top 10 Hldgs %
81.52%
Holding
28
New
2
Increased
17
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$60.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$33.6M
3
PCVX icon
Vaxcyte
PCVX
+$25.8M
4
LQDA icon
Liquidia Corp
LQDA
+$14.7M
5
DVAX
Dynavax Technologies
DVAX
+$13.8M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$13.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$6.77M
3
TYRA icon
Tyra Biosciences
TYRA
+$2.07M
4
COGT icon
Cogent Biosciences
COGT
+$201K

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$259M 19.88%
2,042,471
+28,063
+1% +$3.22M
PCVX icon
2
Vaxcyte
PCVX
$7.89B
$119M 9.1%
1,039,288
+286,048
+38% +$25.8M
CLDX icon
3
Celldex Therapeutics
CLDX
$2.77B
$118M 9.01%
3,458,609
+69,642
+2% +$2.65M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.84B
$112M 8.62%
5,842,925
+120,868
+2% +$2.5M
COGT icon
5
Cogent Biosciences
COGT
$6.79B
$99.8M 7.65%
9,239,731
-20,654
-0.2% -$201K
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$92.8M 7.12%
8,332,687
+1,250,125
+18% +$13.8M
VERA icon
7
Vera Therapeutics
VERA
$2.54B
$69.7M 5.34%
1,576,549
+32,880
+2% +$1.25M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.37B
$69M 5.29%
9,085,368
+258,658
+3% +$1.97M
CGON icon
9
CG Oncology
CGON
$6.11B
$66.8M 5.12%
1,770,805
+1,716,894
+3,185% +$60.2M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$57.1M 4.38%
2,511,295
+761,295
+44% +$12.4M
WVE icon
11
Wave Life Sciences
WVE
$1.12B
$40.2M 3.08%
4,899,497
+923,976
+23% +$5.52M
BEAM icon
12
Beam Therapeutics
BEAM
$2.58B
$31.9M 2.45%
+1,302,085
New +$33.6M
TSVT
13
DELISTED
2seventy bio
TSVT
$28.1M 2.15%
5,953,825
– –
LQDA icon
14
Liquidia Corp
LQDA
$7.67B
$22.7M 1.74%
2,266,328
+1,349,754
+147% +$14.7M
PTGX icon
15
Protagonist Therapeutics
PTGX
$8.75B
$20.5M 1.57%
456,369
-343,631
-43% -$13.9M
TVTX icon
16
Travere Therapeutics
TVTX
$5.33B
$19.2M 1.47%
1,371,511
-650,148
-32% -$6.77M
IRWD icon
17
Ironwood Pharmaceuticals
IRWD
$611M
$15.2M 1.16%
3,685,563
+2,043,672
+124% +$11M
VRTX icon
18
PUT
Vertex Pharmaceuticals
VRTX
$121B
$14M 1.07%
30,000
-300,000
-91% -$144M
ENGN icon
19
enGene Therapeutics
ENGN
$122M
$11.5M 0.88%
+1,736,227
New +$12.9M
TYRA icon
20
Tyra Biosciences
TYRA
$1.82B
$11M 0.84%
467,947
-98,768
-17% -$2.07M
AMRN
21
Amarin Corp
AMRN
$284M
$7.78M 0.6%
620,731
+12,939
+2% +$172K
STRO icon
22
Sutro Biopharma
STRO
$379M
$7.15M 0.55%
206,645
+4,277
+2% +$168K
CRBU icon
23
Caribou Biosciences
CRBU
$156M
$4.62M 0.35%
2,356,147
+709,445
+43% +$1.45M
SLRN
24
DELISTED
ACELYRIN
SLRN
$4.18M 0.32%
847,366
+16,056
+2% +$82.9K
BNR
25
Burning Rock Biotech
BNR
$94.4M
$3.23M 0.25%
989,217
+14,549
+1% +$80.2K
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Kynam Capital Management held 28 positions worth $1.3B, up 0.62% from $1.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Kynam Capital Management withdrew a net $150M in Q3 2024, closing 3 positions and reducing 5 holdings. Its largest reduction was Protagonist Therapeutics, cutting an estimated $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 74% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Beam Therapeutics worth $31.9M.

  • Kynam Capital Management's largest Q3 2024 buy was Beam Therapeutics: 1,302,085 shares worth $31.9M.
  • Kynam Capital Management added most to CG Oncology in Q3 2024, an estimated $60.2M increase.
  • Kynam Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $13.9M.
  • Kynam Capital Management's ten largest holdings make up 82% of its $1.3B portfolio in Q3 2024.
  • Kynam Capital Management opened 2 new positions and closed 3 in Q3 2024.
  • Kynam Capital Management's portfolio value rose 0.62% quarter-over-quarter to $1.3B.

Based on Kynam Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.